Brief: Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical
28/04/2025 14:31
Alpha Tau Medical Ltd DRTS.O: ORAMED PHARMACEUTICALS ANNOUNCES $36.9 MILLION INVESTMENT AND STRATEGIC COLLABORATION WITH ALPHA TAU MEDICAL Source text: ID:nPn5KncZqa Further company coverage: DRTS.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer